Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin

Definitions

• the scope of the invention is not subject to mediation, and this is mainly due to the fact that the drug is being treated in the United States.
• Shi ⁇ ⁇ e is ⁇ lz ⁇ vayaie siya ⁇ e ⁇ iches ⁇ i ⁇ es ⁇ gen ⁇ v 'in ⁇ sledyaie g ⁇ dy ⁇ zv ⁇ lil ⁇ vyyavi ⁇ ⁇ yad se ⁇ ezyay ⁇ ⁇ b ⁇ ch- 15 yay ⁇ i ⁇ deys ⁇ vy.
• the indicated drugs cause gay men and women and harmless people.
• the inventive company possesses the expressed estrogen
• the inventive device stimulates the development of brand and primary female rivals in the event of their underdevelopment. takes on common facilities arising from the lack of
• Declare ⁇ réelle ⁇ ⁇ ... causes the process of synthesis and luteinizing hormones and the stimulating hormones to be activated in the process of gypsy and stimulates the process of evolving.
• the inventive product is absorbed from the gastrointestinal tract and, when used internally, does not possess an irritating effect. In fact, it is not very toxic, it does not possess the reagent and cancerous properties. Declare that you may be
• the claimed preparation was tested in humans and in humans.
• the strenuous activity of the claimed drug was also experienced in mouse trials. At the same time, it was noted that the mass of the brand and increase the weight of the matrices by changing in it.
• the active activity of the claimed product is in the case of obesity and spasms
• the claimed preparation at a dose of 0.05 mg / kg caused leakage / estrus / in two well-developed mice of ulcer 10, at a dose of 0.1 mg / kg in 5 and at a dose of I mg / kg at all time.
• the inventive preparation in doses of 0, I and I mg / kg for 5 days, stresses the manifestation of the effects.
• the 2nd-5th act after the nursing of the males, at $ 80, there are vaginal dabs of the wounds.
• the online group lasts 7-8 days. After the first experience of 19 years, the pregnancy was revealed, that the uncultured voles were found to be invisible, all the living things, I’ve forgotten.
• the claimed preparation which is rooted in the family, causes injuries in food, accelerates the damage to the land and causes loss of health. ⁇ crusts that received I mg / kg of the claimed medication, in which the ⁇ - ⁇ 2 deformity occurs in the large area of a small immigrant, is immature.
• the most pronounced method of treatment was protein metabolism in 20 skeletal muscles, and I studied cardiac arrhythmias.
• the claimed preparation was administered in a dose of I mg / kg internally for 3 days.
• the claimed preparation in the dose of I mg / kg is in good condition that it is free from any loss of health.
• the results of the experiments are presented in tables 3 and 4.
• estegeevy effect is claimed to be a preparation that is judging by the increase in mass, this is a common protein in it, so it is an active protein.
• esthegy is a variable effect during the different seasons of the year.
• the 30th group was able to increase to 20 mg, claimed by the manufacturer and the generator “on the contrary, increasing it already up to 85, 2 and 92, 5 mg, respectively.
• the claimed preparation in the dose I mg / kg was administered at 15.00, the timed stage of diesestus-2 was oversized, and the accumulation was completed after 18 hours (200.9_6.9 ng / ml after 20 hours) 25 3.2 ng / ml), although I am different. thirdly, a third-party hotel in the gizmo.
• the claimed drug was introduced into the estrus-2 estates, and more often than not it was possible to suppress the secretion of ulcerous ulcers.
• ⁇ [- ⁇ ⁇ and introduction of it in a mouse is equal to 2220 mg / kg, for ⁇ 4700 mg / kg. 3 experiences on the occasion
• the claimed preparation does not show the reaction and the terminal action, 5 but also does not affect the process.
• the claimed preparation was pagan in 468 sick women. On-site groups at different clinics provided paired groups of white women who were treated with maternal / ethinyl-esthil / yale disease.
• the invented drug was studied in the Republic of Poland and the English Empire in girls 12-16 years old. The most painful way to start the course is to carry out an examination, including: anesthetics, tests of functional diagnostics; I share the right to make sense, therefore, I was not happy with the external arrogance of six small lips; vaginal for identifying the condition of the neck; ultra-sound scanning of small businesses; Distribution of a wide area.
• the inventive preepa-20 dose was prescribed in a dose of 5-10 mg per day, 20-day courses. Just 1-2 kursa.
• the mammary glands are enlarged to the extent of the enlargement of the mammary glands.
• the genital area was: “counted 25 times” of the mucous membranes of the vulva, except for the vaginal
• the claimed preparation showed an active action - 16 - vyaye on an ugly gang are sick with different siblings ieriaus ⁇ ⁇ ’ 5 Gastrointestinal effects were not earlier than after 3-6 months of untreated treatment. In all patients, an abnormal menstrual reaction was observed. Comply with the sale of the product, there is a softer occupation and I’ll be absent
• the starting 10 gosh,,,, ng / ml 11.0 * 2.6 19.1 * 4.9 8.5 * 2.6 11.0 * 2.7
• the claimed medication was prescribed for 2.5-5 mg ⁇ I nect ⁇ per day for 12-14 days / I phase of the cycle /.
• the claimed product does not suffer from a disastrous effect, has a mild, rapidly growing effect, which is beneficial for the ulcer
• the declared preparations can be used in various medicinal forms / in tablets, candles, and other tablets /. I am the main dozers set yandyuadualno in the wilderness of the form of the disease. ⁇ réelle ⁇ réelle ⁇ Fort strig-
• the claimed drug is indicated for diseases of the small glands and the disease of the mammary gland / get the glands / lapoma, endometrium /.
• the method of allocating an active substance can be accomplished by the following method.
• the claimed and treated product is used in a gynecological treatment for treating diseases associated with a defect in the function of an egg. ⁇ ⁇ tica ⁇

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Emergency Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (6)

Applications Claiming Priority (1)

Publications (1)

Family

ID=21617114

Family Applications (1)

Country Status (6)

Families Citing this family (1)

Citations (3)

• 1987
  • 1987-05-29 JP JP87505402A patent/JPH02500362A/ja active Pending
  • 1987-05-29 DE DE19873790958 patent/DE3790958T1/de not_active Withdrawn
  • 1987-05-29 WO PCT/SU1987/000065 patent/WO1988009164A1/ru active Application Filing
  • 1987-05-29 CH CH3458987A patent/CH672251A5/de not_active IP Right Cessation
  • 1987-10-07 FR FR8713841A patent/FR2621485B1/fr not_active Expired - Fee Related
• 1989
  • 1989-01-26 GB GB8901641A patent/GB2213062B/en not_active Expired - Fee Related

Patent Citations (3)

Also Published As

Similar Documents

Legal Events